LLY:NYSEEli Lilly and Company Analysis

Eli Lilly (LLY) is trading at $922.5, essentially flat on its 20‑day SMA (921.6) but still below the 50‑day SMA (981.7), indicating a short‑term neutral stance. The RSI of 43.7 and a bullish MACD histogram (+5.28) suggest the downside pressure is easing, while decreasing volume hints at a modest lack of conviction among traders. Fundamentally, the company is delivering exceptional growth – revenue surged 42.6% YoY to $65.2 bn, profit margin sits at 31.7% and ROE exceeds 100%, underscoring powerful operating leverage. Forward earnings are projected at $42.02 per share, translating to a forward P/E of 22×, well below the industry average of 26× and implying a ~31% upside to the DCF‑derived fair value. Dividend sustainability looks solid with a 0.68% yield, a modest 26% payout ratio and ample free cash flow, though the balance sheet is leveraged (debt‑to‑equity 165%). The stock’s beta of 0.68 points to lower market‑risk sensitivity, but a 30% 30‑day volatility and recent price corrections keep risk modestly elevated.